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The present manuscript aims to discuss the implications of
sequential knowledge integration of small preclinical trials
in a Bayesian PK-PD framework. Whereas, at first sight, a
Bayesian PK-PD framework seems to be a natural frame-
work to allow for sequential knowledge integration, the
scope of this paper is to highlight some often-overlooked
challenges while at the same time providing some guidances
in themany and overwhelming choices that need to bemade.
Challenges as well as opportunities will be discussed that
are related to the impact of (i) the prior specification, (ii) the
choice of random effects, (iii) the type of sequential integra-
tion method. In addition, it will be shown how the success
of a sequential integration strategy is highly dependent on a
carefully chosen experimental design when small trials are
analyzed.
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1 | INTRODUCTION
Research on pharmacokinetic and pharmacodynamic (PK-PD)models has evolved a lot over the last 50 years, allowing
to better quantify the pharmacodynamic behavior of compounds, thereby facilitating drug development. We refer
to Felmlee et al., Mould et al. and Upton et al. [1, 2, 3] for a brief overview. Although the PK-PD literature has been
originally developed in a frequentist framework using themaximum likelihood (ML) approach, only recently it has been
recognized that Bayesian methods are a powerful tool for drug development [4, 5, 6, 7, 8, 9, 10]. Bayesian methods have
several applications with respect to incorporating the knowledge from previous studies into the current study [11],
such as bridging animal studies and first-in-man studies [12, 13], or using information from clinical studies on adults to
analyze studies on neonates [14].
Previous work [15] illustrates the successful development and application of a Bayesian K-PDmodel for synergy
on in-vivo data where the results from a historical dose-response trial were incorporated through a prior distribution.
The data of all combination trials were collected at the same laboratory and the trials were conducted by the same
scientist. The authors therefore argued that all trials could be pooled and that data could be analyzed together. In
doing so, however, the sequential nature of the data collection, where each trial is conducted at a different point of
time and the results from a trial are used to design the next trial, is completely ignored. The question arises to what
extent a pooled analysis would differ from a (Bayesian) sequential modeling approach. In this paper such Bayesian
sequential approach is first implemented. Whereas the integration of incoming information recursively over time is well
established in the field of computer science under the name of recursive Bayesian estimation [16, 17], the technique has
-to our knowledge- hardly ever been applied in the framework of a complex PK-PDmodeling approach [18]. Micallef et
al. [19] proposed amethod to sequentially update the parameters of a PKmodel for caffeine in premature neonates
using a stochastic particle algorithm. In our work, the Bayesian integration is performed by setting the hyperparameters
of the prior distributions of a trial based on the posterior distributions resulting from the previous trial. Challenges and
opportunities will be outlined in that respect as it is extremely important to understand the behavior and properties of
this methodology on the intermediate results at different integration steps, particularly when small trials are analyzed
with complex nonlinear models. In addition, it is shown that (under certain conditions) both approaches (pooling all data
versus sequential integration) are expected to give similar results. As an important consequence, intermediate results
allow for an adaptive design approach in the sense that they can guide the scientists towards a sensible dosing choice
for the next trial.
Themanuscript has the following structure: Section 2 describes themotivational case study and briefly revisits
themodel proposed by La Gamba et al. [15] to analyze these data; Section 3 describes different modeling aspects and
compares various types of Bayesian sequential pooling. The results from these comparisons are shown in Section 4. A
final discussion is given in Section 5.
2 | MOTIVATING CASE STUDY
This section provides a brief description of the case study (Section 2.1) and the proposed K-PDmodel for synergy by La
Gamba et al. [15] to analyze these data (Section 2.2).
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2.1 | Case study
This study was part of the pre-clinical safety evaluation of a novel compound meant to be co-administered with a
compound already available on themarket [20]. For themarketed compound, a historical trial was available to assess its
safety [21]. An extensive dose range, from 0.04 to 10mg/kg, was investigated. Placebo administration was included
as well. A total of 55 rats were randomly allocated to receive a single dose of the marketed compound. For each of
those rats body temperature, the biomarker of interest, was assessed up to 24 hours after single oral administration. No
plasma concentration-time profiles weremeasured in this trial due to the possible impact of blood sampling on body
temperature. Dose related decrease in body temperature was observed for extremely high doses, indicating potential
side effects beyond the clinical therapeutic window.
With the intent to develop the novel compound for co-administration, 11 new combination trials were conducted
in different time periods to evaluate whether a PD interaction between compounds occurs at different combinations of
dose levels (the absence of a PK interaction had already been confirmed). A new set of 20 rats (from the same vendor
and having the same strain) was used in each trial, with 5 animals randomized to each of four treatment groups. Group 1
received a single dose of the vehicle, group 2 and group 3 received a single dose of themarketed and novel compound
respectively. Finally, group 4 received a combination of both compounds. Body temperature was assessed every hour
after administration for 4 hours. As mentioned above, a different combination of dose levels was assessed in each
trial, to understand this synergistic behavior. Therefore, the 11 combination trials only differ by dose combination
assessed and conduction time period. Table 1 shows the compound doses in each trial, whereas Figure 1 illustrates the
time profiles for the rats belonging to trial 1 as an example. Animals in the vehicle and novel treatment groups did not
show any effect on body temperature, whereas rats attributed to the marketed compound showed an effect in line
with the historical trial. It was, however, unexpected that the combination groupwould have shown a change in body
temperature which wasmore pronounced than themarketed treatment group. Also, the decrease in body temperature
wasmore pronounced in trials assessing higher doses. Therefore, the presence of a PD synergy was hypothesized. We
refer to [15] for amore detailed description of the case study.
2.2 | K-PDmodel for synergy
Let us now describe themodel proposed by La Gamba et al. [15]. This is an example of a Type I indirect PD response
model [22] with an inhibition process operating on the apparent production rate. So, if R i t denotes the observed body
temperature for animal i at time t , then:
R i t ∼ N (R¯ i t ,σ2R ), (1)
d R¯ i t
d t
= k i n
(
1 − ImaxCi t
I C50 + Ci t
)
− kout R¯ i t . (2)
where R¯ i t is the expected body temperature for animal i at time t . The parameters k i n and kout are the rate for
apparent production and elimination of body heat, respectively. Ci t represents the (hypothetical) plasma concentration
of the marketed compound and Imax is the maximal inhibition of the production rate. Finally, I C50 represents the
concentration of the marketed treatment resulting in 50% of the maximal inhibition. The model takes into account
residual error via equation (1), with σ2R themeasurement variance.
As the plasma concentration was not measured, a virtual one-compartment first order absorption PK profile [23]
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was assumed to drive the inhibition of body heat (hence the use of the term "K-PD" in contrast to "PK-PD", to emphasize
the absence of PK data):
dAe,i t
d t
= −kaAe,i t , (3)
dCi t
d t
= kaAe,i t − keCi t , (4)
whereAe,i t represents the hypothetical amount of themarketed compound in the absorption depot; the parameter ka is
the first-order apparent absorption rate constant, whereas the parameter ke is the apparent elimination rate constant.
At time t = 0,Ae,i0 corresponds to the dose of themarketed compound,Ci0 = 0, and R i0 = k i n/kout corresponds
to the fact that body temperature is in a steady state condition prior to administration of the compound. Since the
absorption constant is confoundedwith kout , hence not identifiable, ka was set to a very high value, i.e. to exp(5), which
is consistent to the approach in Jacqmin et al. [23].
It is assumed that the co-administration of the novel compound increases the potency of themarketed compound
for body temperature:
I C50 = exp (αAn,i0 + βAe,i0An,i0) , (5)
whereAn,i0 is the dose of the novel compound for the i t h individual, α represents themain effect attributed to the novel
compound and β is the interaction coefficient, representing the extent at which the effect of the novel compound on the
potency of themarketed compound depends on the dose of themarketed compound itself.
To allow for heterogeneity among animals, a random effect was assumed for body temperature at baseline
R0i ∼ N (R¯0,σ2R0 ).
3 | METHODS
In this section, a sequential integration of the information included in the different trials is discussed. The general idea
is to use the posterior distributions resulting from one trial in order to determine the hyperparameters of the prior
distributions of the next trial.
Compared to the traditional Bayesian pooling previously described by La Gamba et al. [15], the sequential method-
ology requires the application of the K-PDmodel on data from trial 1 as a first step, with the prior distributions based
on the results from the historical trial. Performing a complex nonlinear hierarchical model such as the one described
in Section 2.2 on little data may not be simple, and different aspects should be carefully taken into consideration
duringmodel building: Section 3.1 aims at describing how themodel performance changes according to eliciting prior
distributions with different precision, whereas the impact of assigning random effects on different parameters are
described in Section 3.2. Finally, in Section 3.3 different sequential integration types are illustrated and compared.
The Bayesian model was estimated using the No-U-Turn Sampler (NUTS) algorithm in Stan (rstan version
2.14.1) [24] and the graphic representation wasmade using the statistical software package R (Foundation for Statisti-
cal Computing, Vienna, Austria) version 3.3.3. The Stan code for themodel is reported in Appendix A.
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3.1 | Prior specification
One of the aspects that differentiates Bayesian from frequentist inference is that the parameters are treated as random.
Prior distributions represent the existing knowledge regarding the parameters before the data are collected, as well
as the uncertainty of the knowledge itself; posterior distributions incorporate prior knowledge and the information
coming from the data collected in the current experiment [25].
In case of low sample size, the use of informative prior distributions has proven to solve several performance issues,
such as low power and biased parameter values [26]. In some areas of drug development, prior elicitation constitutes a
crucial phase, since the specification of highly informative prior distributions compensates the small data, thus avoiding
convergence issues in parameter estimation [27]. For example, in pediatric studies Bayesian methods are typically
used to explicitly borrow information from other adult trials or previous pediatric studies [14, 28, 29]. See also Viele et
al. [30], Ibrahim et al. [31], Takeda et al. [32] and Li et al. [33] for a more general overview of benefits resulting from
borrowing historical information in the analysis of the current trial. On the other hand, the use of highly informative
priors in case of low sample size may lead to a domination of the prior, rather than the data, on the posterior inferences.
Therefore, prior elicitation should be cautiously performed in order to avoid the inappropriate introduction of artificial
information whichmay bias the final results [34, 35, 36, 37].
In themanuscript of La Gamba et al. [15], the results from a frequentist analysis of the historical dose-response
data on themarketed compoundwere incorporated in the prior distributions: expected values were set equal to the
point estimates obtained from the analysis; the standard deviations were set equal to the double of standard errors to
down-weigh the information derived from the historical trial, whichwas conducted two decades before the combination
trials. In particular, the priors for ke and kout were assumed log-normally distributed, Imax was assumed to follow a
beta distribution (as 0 ≤ Imax ≤ 1), and a uniform distribution with parameters −10 and 10was used as a prior for α and
β as the historical data contain information on the effect of themarketed compound only, so there is no information
regarding the PD synergy prior to the combination trials. An inverse gamma distribution was used as a prior for the
measurement error variance σ2R , and lognormal and inverse gamma distributions were used as priors for themean and
variance of the random effect (R¯0 and σ2R0 ). The prior distributions for each parameter are illustrated in Table 2.
In drug development, however, such a rich a priori information is not always available: weakly informative priors
are often used to avoid that the results are overly influenced by potentially inaccurate prior distributions, as mentioned
above. This section studies how prior informativeness, i.e, precision, influences parameter estimates and parameter
correlations. Themodel described in Section 2.2 was run specifying three different prior distributions for the parameter
Imax on data from trial 1, 2 and 3 pooled altogether, as these trials are analyzed during the first integration step (as
specified in Section 3.3).
(i) Prior 1 is the prior distribution that was used in La Gamba et al. [15], i.e., a beta distribution with expected value
equal to the point estimate obtained from a frequentist analysis of the historical data, and standard deviation equal
to the double of the standard error (SD = 0.02): P r i or 1 ∼ Bet a(19.574, 174.532).
(ii) Prior 2 has the same expected value as Prior 1, but doubled standard deviation (SD = 0.04):
P r i or 2 ∼ Bet a(3.557, 31.713).
(iii) Prior 3 is a standard uniform distribution, i.e., SD = 0.29: P r i or 3 ∼ Bet a(1, 1).
Parameter estimates and parameter correlations were consequently compared. The reason for the choice of
parameter Imax for the prior specification evaluation is due to the fact that the estimate range of this parameter can be
easily inferred from the historical trial, as it represents themaximal inhibition of body heat production. This eases the
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assessment of the accuracy of the results from each analysis.
3.2 | Choice of random effects
As mentioned in Section 2.2, the K-PD model proposed by La Gamba et al. [15] was performed assuming a random
body temperature at baseline. The choice of allocating random effects to certain parameters is not trivial in complex
nonlinear ordinary differential equation (ODE) hierarchical models. In our case study, for example, the heterogeneity
among animals belonging to the same treatment group could be observed, to some extent, in the temperature trend
slopes asides from the baseline (Figure 1). The initial condition of indirect responsemodels, R i0 = k i n/kout [22], implies
that placing a random effect on R i0 leads to the implicit assumption of a random variation of k i n and kout . However, it is
not possible to detect which physiological parameter varies substantially between subjects solely through a graphical
inspection. Therefore, a model assuming a random effect on kout :
l og (kout i ) ∼ N
(
µl og (kout ),σ
2
l og (kout )
)
,
was comparedwith the random baselinemodel in terms of individual estimates and posterior predictions. Both
models were performed on the eleven trials which were pooled together, keeping the same prior distributions as in the
original analysis of the data [15], as described in the previous section. In particular, µl og (kout ) was normally distributed:
µl og (kout ) ∼ N (1.930, 6.840), whereas σ2l og (kout ) ∼ I nv − Gamma(2.022, 1.186). To ease the comparison, the randombaselinemodel was also run assuming a log-normally distributed random effect:







with priors µl og (R0) ∼ N (3.610, 0.002) and σ2l og (R0) ∼ I nv −Gamma(2.022, 1.186). Compared to the original modelassuming a normally distributed random baseline, the greater a priori inter-individual variability of the latter model
would allow to assess its performance under amore extreme scenario.
Amodel with random k i n was also evaluated, but it could not be fitted due to convergence issues.
3.3 | Sequential Bayesian integration
The aim of this section is to evaluate potentialities and challenges arising from integrating the trials in a Bayesian
sequential framework and to assess the influence of factors such as study sample size or experimental design on the
performance of this technique in comparison to pooling the trials together, originally explored by La Gamba et al. [15].
The methodological framework is as follows: let us suppose to have a number of trials conducted sequentially.
At the first integration step, prior distributions for all parameters are chosen by setting the expected value to the
point estimates obtained from the frequentist analysis of the historical data, whereas standard errors are doubled,
consistently with the work of La Gamba et al. [15] (Table 2). At step s (s = 2, ..., S ) the priors are determined so that
they have the samemean and variance as the posterior distributions obtained from step s − 1. From the second step
onwards, the priors for α and β are assumed normally distributed, as a priori information is available from the previous
integration steps. For all parameters, in case a posterior is found to have 2 ormoremodes, mixtures distributions are
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considered.
In order to explore the impact of different factors on the performance of Bayesian sequential integration, the trials
are sequentially pooled using four different methods which are then compared:
Method 1 This method respects the chronological order in which the trials were conducted (see Table 1). Thus, it
is the most intuitive one and it is the type of sequential integration that would be chosen in practice, as each
analysis would be performed each time new data become available. In order to allow the parameters α and β to be
identifiable (such coefficients can only be estimated in presence of multiple dose combinations of both treatments),
the first three trials are pooled together. Further, Bayesian integration was performed by adding one trial at a time.
Method 2 The eleven trials are integrated one at a time, but a random permutation of the trial order is used. It is
therefore possible to check if the results of the sequential pooling are order-invariant. As before, the first three
trials are pooled to guarantee identifiability of α and β .
Method 3 The trials are sequentially pooled three at a time, following the original trial order. In this way, it is possible
to assess if a higher sample size at each integration step has an impact on the final result.
Method 4 New trials are sampled from the existing data such that each new trial contains one animal from each
treatment group and from every single old trial (thus, for each dose combination tested). As such, a maximum
exploration of the dose combination range can be guaranteed at each step of the sequential integration, allowing to
assess the impact of the experimental design on the final result. Since each original trial contains five rats for each
treatment group, five trials of 44 rats each are created.
Table 3 summarizes the sequential integrationmethods described above.
The rationale behind such comparison is that, if the elicited prior distributions for a trial are good approximations of
the posterior distributions from the previous trial, it is in principle expected that each of the above listed sequential
integration techniques would eventually lead to results which are comparable among each other, and comparable to the
original Bayesian pooling described by La Gamba et al. [15].
To give a formal demonstration, letpi1 (θ |X1)be the posterior distribution of the parameter vectorθ after observing
data at step 1,X1. Using Bayes’ theorem:
pi1 (θ |X1) ∝ L (X1 | θ) pi1 (θ) , (6)
where pi1 (θ) is the prior distribution for θ, which was set based on the results from the analysis of the historical data,
and L (X1 | θ) is the likelihood of the data available during the first integration step given θ. If the posterior in (6) is
used to determine the prior for the analysis of data at step 2:
pi1 (θ |X1) = pi2 (θ) , (7)
it follows that the posterior distribution of θ after observing data at step 2:
pi2 (θ |X1,X2) ∝ L (X2 | θ) pi1 (θ |X1) ∝ L (X2 | θ) L (X1 | θ) pi1 (θ) . (8)
where L (X2 | θ) is the likelihood of data available during the second integration step.
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Using the relationships in (7) and (8), it is possible to determine the posterior distribution at a generic step J :
piJ (θ |X1,X2, ...,XJ ) ∝
J∏
j=1
L (Xj | θ) pi1 (θ) , (9)
which, under the assumption of trial exchangeability, is equal to:
piPJ (θ |X1,X2, ...,XJ ) ∝ L (X1,X2, ...,XJ | θ) pi1 (θ) , (10)
that is, the posterior distribution resulting from the analysis of all trials pooled together.
Although, as shown above, it is theoretically proven that the posterior of the sequential integration should coincide
with the one resulting from pooling the trials together, in complex nonlinear ODE hierarchical models, where several
numerical methods are used in the estimation process and in the approximation of the posterior distributions, incon-
sistency between the twomethods are to be expected. The sequential integration strategiesmentioned abovewere
compared among each other, and to the results of pooling the data altogether, in terms of parameter estimates and
population predicted profiles.
4 | RESULTS
4.1 | Prior specification
The correlationmatrices of the parameters of the K-PDmodel for synergy described in Section 2.2, performed on data
from the first three trials using three different prior distributions for the parameter Imax (with a standard deviation
equal to 0.02, 0.04 and 0.29) are shown in Figures 2, 3 and 4 respectively, whereas Table 4 compares the parameter
estimates.
When a highly informative prior - incorporating the results of the historical trial - is used, the posterior parameter
estimates are nearly uncorrelated: only a weak correlation can be observed between the parameters Imax and β , and
between β and α . When the prior standard deviation is doubled, the correlations between the abovementioned param-
eters, as well as between ke and kout , and between Imax and kout become stronger. These correlations increase even
further when a non-informative (uniform) prior is chosen for Imax . This result shows that the use of highly informative
priors reduces the correlation between parameters, that can compromise the validity of parameter estimation [33]:
whenweakly informative priors are chosen, the estimationmethodmainly relies on the current data and the chosen
model; if the data are sparse, there is a lack of information which leads to a higher correlated parametric space, where
parameters compensate each other. As such, the parameter estimates may be biased even though themodel seems
to fit the data well. For example, it is possible to observe (Table 4) that the increase of Imax (themaximal inhibition of
body heat production) with increasing prior standard deviation is compensated by a decrease in the elimination rate of
body heat kout and an increase in β , which decreases the potency of themarketed treatment. However, it was known
from the analysis of historical data, that Imax could not exceed a value of 0.18. Therefore, the estimates of Imax when
SD = 0.04 andwhen SD = 0.29 cannot be considered reliable.
It should be noted that the low correlation among parameters following the specification of informative priors
might be also due to the fact that the chosen prior distributions did not incorporate the correlations among parameters
(as this would have increased the computational burden), thus setting a null a priori correlation. Such choicemay be
inappropriate in some contexts, but it prevents the above described parameter compensations arising from the use of
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weakly or uninformative priors.
4.2 | Choice of random effects
In this section, the consequences of allocating a random effect on the parameter kout are studied, and the performances
of this random-effects model are compared with themodel with a random baseline in terms of individual estimates and
posterior predictions.
The individual body temperature estimates of data from trial 1 obtained from fitting themodel with random kout
are shown in Figure 5 and comparedwith the individual estimates of the random baselinemodel (Figure 6). Bothmodels
show a good fit to the data, although some slight differences in the fitted trends were detected for the combination
group.
When the posterior predictive profiles were computed (using the random effect mean rather than the subject-
specific values and incorporating the inter-individual variability in the prediction intervals), substantial differences were
observed between the twomodels: when the random effect was allocated to kout (Figure 7), a systematic downward
bias was observed in the prediction of the time profiles belonging to the combination group, whereas such bias is much
reducedwhen the inter-individual heterogeneity was incorporated at a baseline level (Figure 8).
Through the inspection of the distribution of the posterior mean of subject-specific random effects of kout (Figure
9), it was observed that the variable had approximately a bimodal distribution, where the values associated to the
subjects belonging to the combination groupweremuch lower compared to the other treatment groups. This is due
to an overcompensation between the parameters kout and β . In fact, only the combination group gives a contribution
to the estimation of β : body temperature is at its steady state in the vehicle group and in the group that received
the novel treatment only; in the group that received the marketed treatment only, I C50 is equal to 1. Thus, I C50 is
expressed as a function of α and β only for the combination group. Asmentioned in thework of La Gamba et al. [15]
already, negative estimates of α and β imply that the presence of the novel treatment further decreases the body
temperature, if co-administeredwith themarketed treatment. If the random effect is placed at kout , the low values of
the subject-specific random effects for the combination group (meaning a less pronounced dissipation of body heat)
compensate the overly large decrease in body temperature induced by low values of α and β .
Nevertheless, when the posterior predictions are computed, the estimate of k¯out results on average particularly
high in the combination group, thus producing an exaggerated and unrealistic reduction of body temperature.
Such behavior is very likely due to the correlation of the parameter space: specifically, the parameters β , kout and
Imax are highly correlated. The allocation of a random effect to a parameter which is part of the highly correlated
parameter space can lead to a kind of escape route, where the subject-specific values of the random effect compensate
other parameters. In this case, for example, both kout and β compete to the estimation of the larger decrease in body
temperature induced by the co-administration of marketed and novel compounds.
This result suggests that the allocation of the random effects to different parameters highly affects the perfor-
mances of themodel proposed.
It should be observed that the overcompensation among parameter estimates is not specific to the Bayesian
approach, but it may also happen in a frequentist analysis. Such overcompensation, however, could sometimes be
restrained in a Bayesian framework through the use of informative prior distributions, as shown in the previous Section.
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4.3 | Sequential Bayesian integration
The posterior predictions of the resulting model at the end of each sequential Bayesian integration illustrated in section
3.3, on data from trial 1 are shown in Figures 10, 11, 12 and 13, respectively. Graphs displaying the parameter trends
during the sequential integrations are shown in Appendix B.
Figures 10-13 illustrate that themodels resulting from the first three types of sequential integration produce a
substantial systematic underestimation in the predictions of the time profiles belonging to the combination group.
Furthermore, the posterior predictive intervals are very large,meaning a large amount of uncertainty exists in predicting
body temperature trends. Particularly, the models coming from the integration of one and three trials at a time
keeping the original order show very similar predictions; the final model with the permuted trial order shows a lower
underestimation, with narrower predictive intervals.
A noticeable improvement in prediction, however, can be observed for the model resulting from the sequential
integration of five simulated trials containing all possible dose combinations: the underestimation is reduced, as well as
the predictive intervals width. Moreover, the predictions resulting from such type of sequential integration are themost
similar to the original Bayesian pooling described by La Gamba et al. [15] (Figures 6 and 8), although some differences
between the posterior mean of parameters Imax , β and σ2R0 can be noticed (see Appendix B).
Such results could be deemed counterintuitive: as mentioned in Section 3.3, assuming that the elicited prior
distributions at step s (s = 2, ..., S ) are good approximations of the posterior distributions resulting from step s − 1,
all different types of sequential Bayesian integration should lead to results which are equivalent to each other, and
equivalent to the original Bayesian pooling. However, the set of relationships described in Formulas (6) - (10) may not be
valid when the sequential integration is performed on small trials which do not provide enough information to estimate
all parameters. In fact, during the first integration step using Methods 1 to 3, the information for the estimation of
the eight model parameters originates from the assessment of three dose combinations only. Based on only few dose
combinations, theMCMC algorithmmay not be able to find a unique solution for the posterior estimation. This results
in a highly correlated parameter space, and the posterior distributions arising from the first integration stepmight be
biased.
Formally, let us suppose that the data from the first sequential integration step,XI1 , are scarce, or they are in










, pi1 (θ |X1) , (11)
which invalids the set of relationships in (6) - (10). In such scenario, the better performances of a sequential integration
where the whole dose range is evaluated at each step would not be surprising: the time profiles corresponding to
each treatment dose combination provide useful information tomore accurately identify the real exposure-response
relationship, which allows better predictions. As previously mentioned, althoughMethod 4 shows better predictive
performances, the different values observed in some of the final parameter estimates (see Appendix B) suggest that
this last type of sequential integration cannot be considered equivalent to pooling the trials altogether. To guarantee
themaximum accuracy level, an optimal sample size as well as sampling times should be determined, in addition to an
optimal number of dose combinations. This is a topic of further research.
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5 | DISCUSSION
The Bayesian K-PDmodel for synergy described by La Gamba et al. [15] was performed on several preclinical trials
conducted in different time periods. These trials were pooled together, using prior knowledge from a historical dose-
response trial of the marketed compound. In this work, the trials are integrated in a sequential way: the resulting
posterior distributions from a trial are used to determine the priors for the analysis of the following trial. The advantage
of adopting such approach in drug development is that it allows to analyze each trial immediately, instead of waiting for
the end of data collection before running the analysis, or reanalyzing all available data up to the current trial, with a
consequent computational burden. Moreover, the parameter estimates resulting from each sequential analysis step
might be useful information for the design of the next trials. Compared to the stochastic particle algorithm described by
Micallef et al. [19], our method allows to incorporate multiple observations at each integration step: particle filters
are only suitable when very limited data are added at each step; if a higher amount of data is included at once, the
phenomenon called “particle depletion” can occur, i.e., one or few particles have away higher probability, whereas all
the others are not retained after the filtering step. Moreover, prior down-weight can be implemented in the case of
incompatibility between previous information and newly observed data. Despite such benefits, performing Bayesian
sequential integration of small preclinical trials using a nonlinear hierarchical K-PDmodel has several methodological
implications, which were discussed in this manuscript.
The theoretical foundation underlying the use of this technique is that the resultant posterior distributions would
eventually be equivalent to the ones resulting from pooling the trials together. This is valid in case the elicited prior
distributions for a trial are good approximations of the posterior distributions from the previous trial, and under param-
eter identifiability at each integration step. Parameter identifiability is challenging to assess in non-linear hierarchical
models based on ordinary differential equations, and is still object of ongoing research [38]. Although amodel can be
proven to be identifiable when data is pooled together, identifiability issues may arise during the sequential integration,
due to the fact that during the first integration steps the data do not provide enough information for the estimation of
all parameters. To illustrate this, one can consider the situation where only one of few dose combinations provide little
information for the estimation of the interaction coefficient β . For this reason, different precautions should be taken
before and during the sequential integration performance to avoid such identifiability issues.
Firstly, it was shown that the use of weakly or non-informative priors in the analysis of few small trials increased
the parameter correlation, which leads to a situation where some parameters compensate each other, compromising
the accuracy of parameter estimates. This result suggests that, in case of little data during the first integration steps, the
use of informative priors is recommended for identifiability of themodel, as borrowing information from previous trials
reduces the correlation of the parameter space and causes more stability and less convergence problems. On the other
hand, the choice of priors which are too informative leads to a restrictive exploration of the parameter space during
theMCMC sampling, which should be avoided. Thus, a trade-off in terms of prior informativeness should be carefully
chosen by lowering, for example, the precision of the prior distributions representing the information coming from
possible historical studies. A sensitivity analysis of the priors would enable to gain insights in themodel performance in
this respect.
A high parameter correlation is typical in nonlinear hierarchical PK-PD models, especially when sample size is
small or the available dose range is narrow. One of its consequences concerns the fact that placing the random effect
on a parameter that is part of a highly correlated parameter space leads to parameter overcompensation, where the
population parameter on which the random effect is allocated incorporates part of the effect expressed by other
parameters. A way to avoid such aberration is to limit the variability of the highly correlated parameters, by allocating
the random effects on parameters that are easier to estimate, when it is feasible. In our case study, the random baseline
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model had better performances because the temperature at baseline could easily be inferred from the data, and such
parameter was weakly correlated with the others. Moreover, the functional relationship between baseline and kout
allowed the implicit assumption of random slope variability as well.
A careful prior elicitation and random effect allocation may not be enough to warrant an unbiased sequential
integration, especially when the trials are small: such approach is successful only if adequate dose combinations,
sampling times and replications are explored at each integration step. Our analysis showed that one or few fixed dose
combinations per trial were producing biased results, and that such results were dependent on the order in which the
trials were integrated. This highlights the need of thorough study planning, as the integration of a reduced number
of well designed trials would have generatedmore accurate results in shorter time frames. In reality, it is not always
possible to obtain ideally designed data for a number of reasons such as ethical or logistic considerations. In this case, a
more pragmatic approach is required, such as prior elicitation from literature or from previous studies and the use of
informative priors in the initial step of sequential data integration. However, it is crucial to be aware of the pitfalls of
such approach, as stated in the current paper.
It should be noted that, although this manuscript focuses on the Bayesian framework, challenges such as parameter
overcompensation following the choice of the random effect on a parameter that is difficult to estimate, or parameter
identifiability issues arising from the analysis of small data using complex nonlinear models may occur in a frequentist
framework as well. As such, the Bayesian approach allows to prevent some of these issues, if it is possible to borrow
information from previous trials through the use of informative prior distributions.
Themajor limitation of our work is that parameter correlationwas not incorporated through the use ofmultivariate
prior distributions, as this would further increase the computational burden and convergence issues. This may imply a
progressive information loss during the integration steps. However, specifyingmultivariate prior distributions is not
trivial [39], especially in case of different marginal densities (in our case study, lognormal, beta and inverse-gamma
distributions were used). In this respect, approaches such as Bayesian nonparametric techniques may be employed, and
will be object of further research [40].
In conclusion, the sequential integration of PK-PD data in a Bayesian frameworkmay be a promising approach, as it
allows an early assessment of parameter estimates in reduced time frames. The assessment of a wide dose range is
nevertheless advisable, especially in early studies. Further work is being devoted to extending the findings of our case
study tomore general scenarios.
LAGAMBA ET AL. 13
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TABLE 1 Dose levels used in current trials of drug-drug interactions.
trial 1 2 3 4 5 6 7 8 9 10 11
Marketed compound (mg/kg) 10 2.5 10 0.63 10 0.16 2.5 0.63 0.16 0.04 0.04
Novel compound (mg/kg) 40 40 10 40 2.5 40 10 10 10 10 40
TABLE 2 Prior distributions and standard deviations relative to the parameters of the Bayesian K-PDmodel for
synergy, first integration step.
Parameter Prior distribution SD
ke l ogN (−0.115, 0.514) 0.559
kout l ogN (1.930, 6.840) Uni nf ormat iv e?
Imax Bet a(19.574, 174.532) 0.022
R¯0 l ogN (3.61, 0.002) 0.074
α Uni f (−10, 10) 5.773
β Uni f (−10, 10) 5.773
σ2R0
I nv -Gamma(2.022, 1.186) 3.910
σ2R I nv -Gamma(54.441, 24.476) 0.063
? The standard error of the estimate of the parameter kout resulting from the analysis of the historical trial on the
marketed compoundwas high. Therefore, the prior distribution for kout can be considered uninformative.
TABLE 3 Different Bayesian integration strategies evaluated. InMethod 4, each new trial contains one animal from
each treatment group and from every single old trial.
Method Trial integration sequence
1: Original trial order 1, 2, 3→ 4→ 5→ 6→ 7→ 8→ 9→ 10→ 11
2: Random order permutation 5, 3, 8→ 11→ 6→ 1→ 2→ 9→ 7→ 4→ 10
3: Three trials at a time 1, 2, 3→ 4, 5, 6→ 7, 8, 9→ 10, 11
4: Five new trials 1new → 2new → 3new → 4new → 5new
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TABLE 4 Results of the Bayesianmodel performed on data from trials 1, 2 and 3with three different priors for Imax :
posterior mean and standard deviation.
Parameter SD = 0.02, E SS = 194.106 SD = 0.04, E SS = 35.27 SD = 0.29, E SS = 2
ke 0.53 (0.08) 0.55 (0.08) 0.61 (0.10)
kout 1.15 (0.17) 0.91 (0.17) 0.78 (0.16)
Imax 0.15 (0.02) 0.20 (0.03) 0.24 (0.05)
R¯0 37.12 (0.07) 37.15 (0.06) 37.16 (0.06)
α −1.42 (0.40) −1.58 (0.27) −1.55 (0.24)
β −2.85 (2.08) −0.51 (0.89) −0.13 (0.56)
σ2R0
0.31 (0.08) 0.26 (0.07) 0.25 (0.07)
σ2R 0.41 (0.03) 0.41 (0.03) 0.41 (0.03)
SD: standard deviation; ESS: Prior’s Effective Sample Size.
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Vehicle Novel treatment Marketed treatment Combination



































F IGURE 1 Time profiles of the individuals from trial 1: the first column represents the animals belonging to the
vehicle group; the second and third columns show the animals assigned to the novel andmarketed treatment,
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F IGURE 2 Impact of prior (prior 1): Correlationmatrix relative to the parameters of the K-PDmodel for synergy.
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F IGURE 3 Impact of prior (prior 2): Correlationmatrix relative to the parameters of the K-PDmodel for synergy.
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F IGURE 4 Impact of prior (prior 3): Correlationmatrix relative to the parameters of the K-PDmodel for synergy.
Vehicle Novel treatment Marketed treatment Combination







































F IGURE 5 Impact of random effect (random kout ): Individual estimates (solid line) and credible intervals (grey
bands), trial 1.
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Vehicle Novel treatment Marketed treatment Combination







































F IGURE 6 Impact of random effect (random R0): Individual estimates (solid line) and credible intervals (grey bands),
trial 1.
Vehicle Novel treatment Marketed treatment Combination







































F IGURE 7 Impact of random effect (random kout ): Posterior predictions (solid line) and posterior predictive
intervals (grey bands), trial 1.
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Vehicle Novel treatment Marketed treatment Combination

















































F IGURE 8 Impact of random effect (random R0): Posterior predictions (solid line) and posterior predictive intervals

























F IGURE 9 Kernel density estimation of the distribution of the posterior means of the subject-specific random
effects values relative to trial 1, using themodel with random R0 (upper) and themodel with random kout (lower). The
arrows represent the posterior estimates of the values for the subjects belonging to the combination group.
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F IGURE 10 Impact of sequential integration (method 1): Posterior predictions (solid line) and posterior predictive
intervals (grey bands), trial 1.
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F IGURE 11 Impact of sequential integration (method 2): Posterior predictions (solid line) and posterior predictive
intervals (grey bands), trial 1.
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F IGURE 12 Impact of sequential integration (method 3): Posterior predictions (solid line) and posterior predictive
intervals (grey bands), trial 1.
Vehicle Novel treatment Marketed treatment Combination







































F IGURE 13 Impact of sequential integration (method 4): Posterior predictions (solid line) and posterior predictive
intervals (grey bands), trial 1.
